[1]
Cugurra F. [Drug therapy and affective disorders: state of the art]. La Clinica terapeutica. 1995 Oct:146(10):577-85
[PubMed PMID: 8590559]
[3]
Li X, Wang Q, Hu T, Wang Y, Zhao J, Lu J, Pei G. A tricyclic antidepressant, amoxapine, reduces amyloid-β generation through multiple serotonin receptor 6-mediated targets. Scientific reports. 2017 Jul 10:7(1):4983. doi: 10.1038/s41598-017-04144-3. Epub 2017 Jul 10
[PubMed PMID: 28694424]
[4]
Ahmad S, Hughes MA, Yeh LA, Scott JE. Potential repurposing of known drugs as potent bacterial β-glucuronidase inhibitors. Journal of biomolecular screening. 2012 Aug:17(7):957-65. doi: 10.1177/1087057112444927. Epub 2012 Apr 24
[PubMed PMID: 22535688]
[5]
Kong R, Liu T, Zhu X, Ahmad S, Williams AL, Phan AT, Zhao H, Scott JE, Yeh LA, Wong ST. Old drug new use--amoxapine and its metabolites as potent bacterial β-glucuronidase inhibitors for alleviating cancer drug toxicity. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Jul 1:20(13):3521-30. doi: 10.1158/1078-0432.CCR-14-0395. Epub 2014 Apr 29
[PubMed PMID: 24780296]
[6]
Mika J, Zychowska M, Makuch W, Rojewska E, Przewlocka B. Neuronal and immunological basis of action of antidepressants in chronic pain - clinical and experimental studies. Pharmacological reports : PR. 2013:65(6):1611-21
[PubMed PMID: 24553009]
[7]
van Wyk EM, Louw DA. Amoxapine in the treatment of depression. A clinical evaluation in ambulant patients. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde. 1982 Jun 12:61(24):908-11
[PubMed PMID: 7046092]
[8]
Kapoor R, Peyear TA, Koeppe RE 2nd, Andersen OS. Antidepressants are modifiers of lipid bilayer properties. The Journal of general physiology. 2019 Mar 4:151(3):342-356. doi: 10.1085/jgp.201812263. Epub 2019 Feb 22
[PubMed PMID: 30796095]
[9]
Richelson E, Nelson A. Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. The Journal of pharmacology and experimental therapeutics. 1984 Jul:230(1):94-102
[PubMed PMID: 6086881]
[10]
Reeves KC, Virk S, Niedermier J, Duchemin AM. Addition of amoxapine improves positive and negative symptoms in a patient with schizophrenia. Therapeutic advances in psychopharmacology. 2013 Dec:3(6):340-2. doi: 10.1177/2045125313499363. Epub
[PubMed PMID: 24294487]
Level 3 (low-level) evidence
[12]
Ban TA, Fujimori M, Petrie WM, Ragheb M, Wilson WH. Systematic studies with amoxapine, a new antidepressant. International pharmacopsychiatry. 1982:17(1):18-27
[PubMed PMID: 7045016]
Level 1 (high-level) evidence
[13]
Apiquian R, Fresan A, Ulloa RE, de la Fuente-Sandoval C, Herrera-Estrella M, Vazquez A, Nicolini H, Kapur S. Amoxapine as an atypical antipsychotic: a comparative study vs risperidone. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2005 Dec:30(12):2236-44
[PubMed PMID: 15956984]
Level 2 (mid-level) evidence
[14]
Ban TA, Wilson WH, McEvoy JP. Amoxapine: a review of literature. International pharmacopsychiatry. 1980:15(3):166-70
[PubMed PMID: 7016801]
[15]
Ragheb M, Wilson WH, Ban TA, Brannen JO. Amoxapine: once versus divided daily doses in neurotic and endogenous depression. The Journal of clinical psychiatry. 1981 Aug:42(8):318-21
[PubMed PMID: 7019201]
[16]
ACOG Committee on Practice Bulletins--Obstetrics. ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation. Obstetrics and gynecology. 2008 Apr:111(4):1001-20. doi: 10.1097/AOG.0b013e31816fd910. Epub
[PubMed PMID: 18378767]
[18]
By the 2023 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2023 Jul:71(7):2052-2081. doi: 10.1111/jgs.18372. Epub 2023 May 4
[PubMed PMID: 37139824]
[19]
Aono T, Kaneko M, Numata Y, Takahashi Y, Yamamoto T, Kumashiro H. Effects of amoxapine, a new antidepressant, on pseudoneurotic schizophrenia. Folia psychiatrica et neurologica japonica. 1981:35(2):115-21
[PubMed PMID: 7026396]
[20]
Hekimian LJ, Weise CC, Friedhoff AJ. Onset of action of amoxapine and doxepin in outpatients with "mixed anxiety/depression". The Journal of clinical psychiatry. 1983 Jul:44(7):248-52
[PubMed PMID: 6863224]
[21]
Obara K, Imanaka S, Fukuhara H, Yamaki F, Matsuo K, Yoshio T, Tanaka Y. Evaluation of the potentiating effects of antidepressants on the contractile response to noradrenaline in guinea pig urethra smooth muscles. Clinical and experimental pharmacology & physiology. 2019 May:46(5):444-455. doi: 10.1111/1440-1681.13072. Epub 2019 Mar 7
[PubMed PMID: 30737814]
[22]
Obara K, Michino M, Ito M, Ao L, Sawada A, Yamaki F, Matsuo K, Yoshio T, Tanaka Y. Evaluation of Antidepressant Effects on Recovery of Electrical Field Stimulation-Induced Contractions that have been Suppressed by Clonidine in Isolated Rat Vas Deferens. Pharmacology. 2019:103(3-4):189-201. doi: 10.1159/000495616. Epub 2019 Jan 29
[PubMed PMID: 30695779]
[23]
Demyttenaere K, Huygens R. Painful ejaculation and urinary hesitancy in association with antidepressant therapy: relief with tamsulosin. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2002 Aug:12(4):337-41
[PubMed PMID: 12126873]
[24]
Johannessen Landmark C, Henning O, Johannessen SI. Proconvulsant effects of antidepressants - What is the current evidence? Epilepsy & behavior : E&B. 2016 Aug:61():287-291. doi: 10.1016/j.yebeh.2016.01.029. Epub 2016 Feb 24
[PubMed PMID: 26926001]
[25]
Górska N, Słupski J, Cubała WJ, Wiglusz MS, Gałuszko-Węgielnik M. Antidepressants in epilepsy. Neurologia i neurochirurgia polska. 2018 Nov-Dec:52(6):657-661. doi: 10.1016/j.pjnns.2018.07.005. Epub 2018 Aug 11
[PubMed PMID: 30131174]
[27]
Obers S, Staudacher I, Ficker E, Dennis A, Koschny R, Erdal H, Bloehs R, Kisselbach J, Karle CA, Schweizer PA, Katus HA, Thomas D. Multiple mechanisms of hERG liability: K+ current inhibition, disruption of protein trafficking, and apoptosis induced by amoxapine. Naunyn-Schmiedeberg's archives of pharmacology. 2010 May:381(5):385-400. doi: 10.1007/s00210-010-0496-7. Epub 2010 Mar 13
[PubMed PMID: 20229012]
[28]
Serlin DC, Heidelbaugh JJ, Stoffel JT. Urinary Retention in Adults: Evaluation and Initial Management. American family physician. 2018 Oct 15:98(8):496-503
[PubMed PMID: 30277739]
[29]
Dai Z, Abate MA, Long DL, Smith GS, Halki TM, Kraner JC, Mock AR. Quantifying enhanced risk from alcohol and other factors in polysubstance-related deaths. Forensic science international. 2020 Aug:313():110352. doi: 10.1016/j.forsciint.2020.110352. Epub 2020 May 31
[PubMed PMID: 32590196]
[30]
Poh BH, Lee JH, Abdul Haium AA, Choo TLJ. Complete Heart Block Secondary to Flecainide Toxicity: Is It Time for CYP2D6 Genotype Testing? Pediatrics. 2020 Jul:146(1):. pii: e20192608. doi: 10.1542/peds.2019-2608. Epub 2020 Jun 19
[PubMed PMID: 32561613]
[31]
. Drug interactions with selective serotonin reuptake inhibitors, especially with other psychotropics. Prescrire international. 2001 Feb:10(51):25-31
[PubMed PMID: 11503857]
[32]
Revet A, Montastruc F, Roussin A, Raynaud JP, Lapeyre-Mestre M, Nguyen TTH. Antidepressants and movement disorders: a postmarketing study in the world pharmacovigilance database. BMC psychiatry. 2020 Jun 16:20(1):308. doi: 10.1186/s12888-020-02711-z. Epub 2020 Jun 16
[PubMed PMID: 32546134]
[33]
Oruch R, Pryme IF, Engelsen BA, Lund A. Neuroleptic malignant syndrome: an easily overlooked neurologic emergency. Neuropsychiatric disease and treatment. 2017:13():161-175. doi: 10.2147/NDT.S118438. Epub 2017 Jan 16
[PubMed PMID: 28144147]
[34]
Janati AB, Alghasab N, Osman A. Neuroleptic malignant syndrome caused by a combination of carbamazepine and amitriptyline. Case reports in neurological medicine. 2012:2012():183252. doi: 10.1155/2012/183252. Epub 2012 Jul 24
[PubMed PMID: 22953086]
Level 3 (low-level) evidence
[35]
Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Bond DJ, Frey BN, Sharma V, Goldstein BI, Rej S, Beaulieu S, Alda M, MacQueen G, Milev RV, Ravindran A, O'Donovan C, McIntosh D, Lam RW, Vazquez G, Kapczinski F, McIntyre RS, Kozicky J, Kanba S, Lafer B, Suppes T, Calabrese JR, Vieta E, Malhi G, Post RM, Berk M. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar disorders. 2018 Mar:20(2):97-170. doi: 10.1111/bdi.12609. Epub 2018 Mar 14
[PubMed PMID: 29536616]
[36]
Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Azorin JM, Yatham L, Mosolov S, Möller HJ, Kasper S, Members of the WFSBP Task Force on Bipolar Affective Disorders Working on this topic. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Acute and long-term treatment of mixed states in bipolar disorder. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry. 2018 Feb:19(1):2-58. doi: 10.1080/15622975.2017.1384850. Epub 2017 Nov 3
[PubMed PMID: 29098925]
[37]
Rochoy M, Zakhem-Stachera C, Béné J, Berkhout C, Gautier S, Réseau français des Centres Régionaux de Pharmacovigilance. [Antidepressive agents and hyponatremia: A literature review and a case/non-case study in the French Pharmacovigilance database]. Therapie. 2018 Oct:73(5):389-398. doi: 10.1016/j.therap.2018.02.006. Epub 2018 Mar 1
[PubMed PMID: 29773358]
Level 3 (low-level) evidence
[38]
Trivedi MH. Tools and strategies for ongoing assessment of depression: a measurement-based approach to remission. The Journal of clinical psychiatry. 2009:70 Suppl 6():26-31. doi: 10.4088/JCP.8133su1c.04. Epub
[PubMed PMID: 19922741]
[39]
Stone MB, Yaseen ZS, Miller BJ, Richardville K, Kalaria SN, Kirsch I. Response to acute monotherapy for major depressive disorder in randomized, placebo controlled trials submitted to the US Food and Drug Administration: individual participant data analysis. BMJ (Clinical research ed.). 2022 Aug 2:378():e067606. doi: 10.1136/bmj-2021-067606. Epub 2022 Aug 2
[PubMed PMID: 35918097]
Level 1 (high-level) evidence
[40]
Kassim T, Mahfood Haddad T, Rakhra A, Kabach A, Qurie A, Selim M, Nayfeh AS, Aly A, Holmberg MJ. A Case of Amitriptyline-induced Myocarditis. Cureus. 2018 Jun 19:10(6):e2840. doi: 10.7759/cureus.2840. Epub 2018 Jun 19
[PubMed PMID: 30430045]
Level 3 (low-level) evidence
[41]
Nelson JC, Spyker DA. Morbidity and Mortality Associated With Medications Used in the Treatment of Depression: An Analysis of Cases Reported to U.S. Poison Control Centers, 2000-2014. The American journal of psychiatry. 2017 May 1:174(5):438-450. doi: 10.1176/appi.ajp.2016.16050523. Epub 2017 Jan 31
[PubMed PMID: 28135844]
Level 3 (low-level) evidence
[42]
Matsuoka M, Imai T, Iwabuchi S, Kinoshita K. Successful Treatment of Amoxapine-Induced Intractable Seizures With Intravenous Lipid Emulsion. The Journal of emergency medicine. 2023 Jan:64(1):62-66. doi: 10.1016/j.jemermed.2022.10.016. Epub 2022 Nov 28
[PubMed PMID: 36450616]
[43]
Sohn JT. Half-Life of Lipid Emulsions Used in Lipid Emulsion Treatment for Drug Toxicity. The Journal of emergency medicine. 2023 Feb:64(2):253-254. doi: 10.1016/j.jemermed.2022.12.032. Epub
[PubMed PMID: 36906377]
[44]
Buckley NA, McManus PR. Can the fatal toxicity of antidepressant drugs be predicted with pharmacological and toxicological data? Drug safety. 1998 May:18(5):369-81
[PubMed PMID: 9589848]
[45]
Curry SC, Brooks DE, Skolnik AB, Gerkin RD, Glenn S. Effect of a medical toxicology admitting service on length of stay, cost, and mortality among inpatients discharged with poisoning-related diagnoses. Journal of medical toxicology : official journal of the American College of Medical Toxicology. 2015 Mar:11(1):65-72. doi: 10.1007/s13181-014-0418-z. Epub
[PubMed PMID: 25127915]